Talazoparib with enzalutamide for previously untreated homologous recombination repair-mutated metastatic hormonal-sensitive prostate cancer

Talazoparib in combination with enzalutamide is in clinical development for the treatment of homologous recombination repair (HRR)-mutated metastatic hormonal-sensitive prostate cancer (mHSPC). Prostate cancer is a cancer of the prostate gland and is the most common type of cancer in men in the UK. The cancer is called metastatic when it has spread to other parts of the body. mHSPC means the cancer is being controlled by keeping the testosterone level as low as would be expected if the testicles were removed. Alterations to the HRR pathway (a mechanism by which DNA damage is repaired) are common in metastatic prostate cancer and may be associated with poorer outcomes. There is therefore a need to develop new treatment options for this population.